Moria inspection ends with five FDA observations as estimate puts 45% of Zydus’ US sales at risk
Key Facts
Zydus Lifesciences disclosed on October 13 that the US Food and Drug Administration’s inspection of its Moria plant had ended with five observations, following a visit from October 5 to 13, 2026. The company said it would work closely with the agency to address the observations quickly, without disclosing their nature or operational impact in its filing. Press coverage based on the inspection form addressed topics including data documentation, investigations, laboratory controls and raw materials. The technical details therefore remain attributed to that coverage, not to the company’s statement. The inspection has commercial significance because Moria products are sold in the US, where a press report estimated that about 45% of Zydus’ sales come from products manufactured at the facility.
Among the issues cited in the coverage was microbial growth that appeared during testing but was not accurately documented in laboratory records. It also cited deficiencies in the investigation of a complaint about metal shavings found in a tablet, an incident the report said led to a Class II recall. On production controls, the report said multiple batches were released to the US market despite exceeding analytical control limits, without an adequate investigation to determine root causes. These details show the scope of the observations as reported in the coverage, but do not represent a list published by the company in its filing. The company said it would work with the FDA to address them, without announcing a new operational action or recall in its filing.
The coverage added that the plant had no written procedures for identifying, investigating and reporting suspected drug products. It also said documented performance qualification of FTIR instruments used to identify raw materials had not been conducted for three years. It further reported that reduced testing of incoming raw materials continued despite previous failures to meet specifications, contrary to the company’s procedures. These observations link the handling of test results, instrument qualification and inspection of materials entering production. But the official filing was limited to the number of observations and the company’s pledge to address them, and did not specify whether these issues would affect production or supply.
The current inspection follows an earlier visit to Moria from July 26 to August 5, 2022, which ended with four Form 483 observations, according to the company’s disclosure about that visit. The company said at the time that none of the four observations related to data integrity. It also said in its annual report that the facility had successfully completed two FDA inspections during fiscal year 2022-23. The number of observations disclosed in the latest inspection was therefore higher than in the 2022 inspection, while the company’s account of the nature of the earlier observations differed. The FDA says Form 483 records inspectors’ observations and does not constitute a final agency determination that a violation of the Federal Food, Drug, and Cosmetic Act exists.
Moria’s share of US sales remains a press estimate, not a figure confirmed by Zydus. NDTV Profit estimated the share at about 45%, while Business Upturn said estimates of exposure varied, citing a range of 20% to 35% in one analysis and 30% to 45% in media reports. The company confirmed none of these percentages, so they cannot be treated as a disclosure of the facility’s share of revenue. Business Upturn also linked the plant’s importance to its role as the company’s center for transdermal patch products. The report said pending approvals for products manufactured at the unit could be delayed if the FDA withheld approvals, a possibility raised by the report and not a decision announced by the agency.
Stock readings during the October 26 session reflected two different moves at relatively close times. At 11:09 a.m., Business Upturn said the stock stood at 1,108.00 rupees, down 1.89% from the previous close of 1,129.40 rupees, after touching a session low of 1,093.50 rupees. Then, at 11:45 a.m., NDTV Profit reported that the stock was up 0.90% at 1,138.00 rupees on the BSE. These readings mean that describing the session as a sustained decline or relying on a single drop percentage would not reflect the stock’s movement at the two reported times. Zydus’ board had announced that its November 4, 2026 meeting would consider unaudited financial results for the second quarter of fiscal year 2027. The FDA also says companies are encouraged to submit a written response with a corrective action plan, and that the company’s response and other evidence factor into the agency’s assessment of any subsequent regulatory action.